|
13 May 2020 |
First Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors
|
|
13 May 2020 |
Alvotech announces positive top-line results for two comparative studies for AVT02, a proposed biosimilar to HUMIRA® (adalimumab)
|
|
12 May 2020 |
Sarclisa (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma
|
|
11 May 2020 |
AstraZeneca recovery of global rights to brazikumab (MEDI2070) from Allergan completed
|
|
11 May 2020 |
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer
|
|
10 May 2020 |
Sorrento And Mount Sinai Health System To Jointly Develop COVI-SHIELD™ Antibody Therapy Targeting SARS-CoV-2 Infection (COVID-19)
|
|
10 May 2020 |
Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes
|
|
08 May 2020 |
European Commission Approves Subcutaneous Formulation of Entyvio® (Vedolizumab) for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
|
|
07 May 2020 |
Tyvyt® (Sintilimab Injection) Combined with Gemzar® (Gemcitabine for Injection) and Platinum Chemotherapy Met the Predefined Primary Endpoint in the Phase 3 ORIENT-12 Study as First-Line Therapy in Patients with Locally Advanced or Metastatic Squamous Non
|
|
07 May 2020 |
Bausch + Lomb licenses exclusive rights from STADA and Xbrane to a biosimilar candidate for Lucentis (ranibizumab) in the United States and Canada
|
|
07 May 2020 |
Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
|
|
06 May 2020 |
Scholar Rock Announces Initiation of Patient Dosing in Phase 1 Proof-of-Concept Immuno-Oncology Trial of SRK-181 to Overcome Primary Resistance to Anti-PD-(L)1 Therapy
|
|
05 May 2020 |
NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors
|
|
05 May 2020 |
Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma
|
|
05 May 2020 |
Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic
|
|
04 May 2020 |
Aridis Pharmaceuticals Enrolls Its First COVID-19 Patient in Ongoing Phase 3 AR-301 Clinical Trial in Ventilator Associated Pneumonia (VAP)
|
|
04 May 2020 |
Teva and Celltrion Healthcare Announce the Launch of TRUXIMA® (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan® (rituximab) Available in the United States for This Indication
|
|
04 May 2020 |
Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine
|
|
04 May 2020 |
Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19
|
|
04 May 2020 |
AbCellera Receives $175.6 Million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody Drugs
|
|
04 May 2020 |
Utrecht University, Erasmus Medical Center and Harbour BioMed Researchers Report Discovery of Antibody that Blocks Novel Coronavirus SARS-CoV-2 Infection in Cells
|
|
04 May 2020 |
Richter entered into an asset purchase agreement with Mycenax for the biosimilar tocilizumab
|
|
02 May 2020 |
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
|
|
01 May 2020 |
CHMP Grants Positive Opinion for DARZALEX®(daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma
|
|
01 May 2020 |
Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
|
